Payment overview · 2025
General Payments
$1,378.58
93 reported records · 16 companies
Healthcare provider profile · identity verified
Rakesh P Shah, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · NEW PORT RICHEY, FL · NPI 1497748719
Verified facts
What the public records show
CMS Open Payments records show Rakesh P Shah, M.D. received $1,378.58 in general payments during 2025 across 93 reported records.
Neurocrine BioSciences, Inc. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa, Hizentra, Ingrezza, Nurtec Odt.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Fycompa by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Hizentra by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $232.29 | 16.9% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $180.47 | 13.1% | 17 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $173.71 | 12.6% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.49 | 9.9% | 10 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $127.71 | 9.3% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $91.54 | 6.6% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $74.68 | 5.4% | 4 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.56 | 4.4% | 6 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $60.39 | 4.4% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $52.26 | 3.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $51.77 | 3.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.88 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.20 | 2.8% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $18.12 | 1.3% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.83 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.68 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,297.09 | 92 |
| Education | $81.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $232.29 | 21 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $180.47 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $180.47 | 17 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $136.49 | 10 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $127.71 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $92.22 | 8 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $91.54 | 4 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $60.56 | 6 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $60.39 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $50.88 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Hizentra hizentra |
2025 | Hizentra | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 440 | 102 |
| Donepezil Hcl | Donepezil Hcl | 391 | 105 |
| Levetiracetam | Levetiracetam | 266 | 63 |
| Primidone | Primidone | 235 | 60 |
| Gabapentin | Gabapentin | 234 | 53 |
| Memantine Hcl | Memantine Hcl | 220 | 53 |
| Topiramate | Topiramate | 112 | 24 |
| Lacosamide | Lacosamide | 103 | 11 |
| Clonazepam | Clonazepam | 96 | 15 |
| Baclofen | Baclofen | 86 | 27 |
| Zonisamide | Zonisamide | 86 | suppressed |
| Lamotrigine | Lamotrigine | 79 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 20 |
| Oxcarbazepine | Oxcarbazepine | 75 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 55 | suppressed |
| Copaxone | Glatiramer Acetate | 52 | suppressed |
| Pregabalin | Pregabalin | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | 16 |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Rivastigmine | Rivastigmine | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 16 |
| Naproxen | Naproxen | 38 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 29 | suppressed |
| Fycompa | Perampanel | 28 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 22 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Betaseron | Interferon Beta-1b | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 16 | suppressed |
| Dalfampridine Er | Dalfampridine | 15 | suppressed |
| Clobazam | Clobazam | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,378.58 · 93 records | Neurocrine BioSciences, Inc. | AUSTEDO XR, BRIUMVI, Briviact, CREXONT, FYCOMPA, HYQVIA, Hizentra, INGREZZA, KESIMPTA, Motpoly XR, NURTEC ODT, Ocrevus Zunovo, PONVORY, Rystiggo, Tascenso ODT, VYEPTI, ZAVZPRET, Zilbrysq | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CATALYST PHARMACEUTICALS, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error